Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
IPO Year: 2021
Exchange: NASDAQ
Website: https://www.centessa.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/20/2024 | $11.00 → $26.00 | Equal-Weight → Overweight | Morgan Stanley |
| 9/19/2024 | $33.00 | Buy | B. Riley Securities |
| 7/18/2024 | $14.00 | Outperform | Oppenheimer |
| 11/15/2023 | $4.00 → $11.00 | Hold → Buy | Jefferies |
| 10/26/2023 | $4.00 → $8.00 | Underweight → Equal-Weight | Morgan Stanley |
| 6/21/2023 | Outperform | Evercore ISI | |
| 6/12/2023 | $9.00 | Buy | Guggenheim |
| 3/17/2023 | $6.00 | Outperform | SVB Securities |
| 8/12/2022 | $10.00 → $5.00 | Overweight → Underweight | Morgan Stanley |
| 6/17/2022 | $19.00 | Outperform | BMO Capital Markets |
BOSTON and LONDON, June 10, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that John Crowley CPA, has been appointed Chief Financial Officer, and Gregory Weinhoff MD MBA, former Chief Financial Officer, has been appointed to the newly created role of Chief Business Officer, effective June 10, 2024. "With all three of our core programs in the clinic, we believe we have solidified a strong foundation and are poised for our next exciting chapter as a company. To best position Centessa for this pivotal time, we've added key new talen
BOSTON and LONDON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the appointment of April Dovholuk and Ellie Im, MD to Centessa's executive team as Senior Vice President of Development Operations and Senior Vice President of Clinical Development, Oncology, respectively. In these newly created roles, Ms. Dovholuk will lead both Centessa's global Clinical Trials and Development Operations teams, and Dr. Im will manage clinical development of the Company's Oncology programs based on the LockBody® technology platform. "We a
Naming the first of three business leaders for its newly created market segments and nominating new Independent Director to its Board LONDON, March 23, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust, today announced that Gordon Samson, currently Chief Product Officer, has been appointed President of its Intellectual Property (IP) market segment, effective April 1. The Company also announced that it has nominated Dr. Saurabh Saha to stand for election as a director at its 2023 Annual General Meeting of shareholders on May 4, 2023.
BOSTON and LONDON, March 01, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the appointment of Patrick Yue, MD, to Centessa's management team as Senior Vice President of Clinical Development, Innovative Medicines. "This is an exciting time for Centessa as we are focused on the next set of clinical milestones, including executing the pivotal program for our lead product candidate, SerpinPC for hemophilia, initiating the Phase 1/2a clinical studies for LB101, our first LockBody® candidate for solid tumors, and progressing MGX292 fo
BOSTON and LONDON, July 25, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company with a Research & Development (R&D) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, today announced the appointment of Harris L. Rotman, PhD, as Senior Vice President, Regulatory Affairs. "We are very pleased to welcome Harris to our leadership team as we prepare for our SerpinPC program in Hemophilia B to move into registrational studies this year and continue to steadily advance our innovative rare disease and immuno-oncology pipeline," said Saurabh Saha, MD, PhD, Chief Executive Officer of Cente
BOSTON and LONDON, July 01, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company with a Research & Development ("R&D") innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, today announced the appointment of Mathias Hukkelhoven, Ph.D., formerly Senior Vice President, Global Regulatory, Safety & Biometrics at Bristol Myers Squibb (BMS), to its Board of Directors. In addition, the Company announced that Aaron Kantoff has resigned from the Company's Board, but will remain actively involved with the Company as an advisor. Both changes are effective July 1, 2022. "I am very pleased to we
Scorpion Therapeutics, Inc. ("Scorpion Therapeutics"), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced the appointment of Saurabh Saha, M.D., Ph.D. to its Board of Directors. Dr. Saha is currently the Chief Executive Officer of Centessa Pharmaceuticals plc (NASDAQ:CNTA) ("Centessa") and brings more than 20 years of biopharmaceutical research and development expertise to the role. "We are pleased to welcome Dr. Saha to our Board of Directors," said Axel Hoos, M.D., Ph.D., Chief Executive Officer of Scorpion Therapeutics. "His passion for discovering new cancer treatments, coupled with his track record o
Morgan Stanley upgraded Centessa Pharmaceuticals from Equal-Weight to Overweight and set a new price target of $26.00 from $11.00 previously
B. Riley Securities initiated coverage of Centessa Pharmaceuticals with a rating of Buy and set a new price target of $33.00
Oppenheimer initiated coverage of Centessa Pharmaceuticals with a rating of Outperform and set a new price target of $14.00
Jefferies upgraded Centessa Pharmaceuticals from Hold to Buy and set a new price target of $11.00 from $4.00 previously
Morgan Stanley upgraded Centessa Pharmaceuticals from Underweight to Equal-Weight and set a new price target of $8.00 from $4.00 previously
Evercore ISI initiated coverage of Centessa Pharmaceuticals with a rating of Outperform
Guggenheim initiated coverage of Centessa Pharmaceuticals with a rating of Buy and set a new price target of $9.00
SVB Securities initiated coverage of Centessa Pharmaceuticals with a rating of Outperform and set a new price target of $6.00
Morgan Stanley downgraded Centessa Pharmaceuticals from Overweight to Underweight and set a new price target of $5.00 from $10.00 previously
BMO Capital Markets initiated coverage of Centessa Pharmaceuticals with a rating of Outperform and set a new price target of $19.00
SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)
SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)
SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)
SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)
SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)
SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)
SC 13G - Centessa Pharmaceuticals plc (0001847903) (Subject)
SC 13G - Centessa Pharmaceuticals plc (0001847903) (Subject)
SC 13G - Centessa Pharmaceuticals plc (0001847903) (Subject)
SC 13G - Centessa Pharmaceuticals plc (0001847903) (Subject)
8-K - Centessa Pharmaceuticals plc (0001847903) (Filer)
10-Q - Centessa Pharmaceuticals plc (0001847903) (Filer)
144 - Centessa Pharmaceuticals plc (0001847903) (Subject)
10-Q/A - Centessa Pharmaceuticals plc (0001847903) (Filer)
144 - Centessa Pharmaceuticals plc (0001847903) (Subject)
424B5 - Centessa Pharmaceuticals plc (0001847903) (Filer)
8-K - Centessa Pharmaceuticals plc (0001847903) (Filer)
424B5 - Centessa Pharmaceuticals plc (0001847903) (Filer)
S-3ASR - Centessa Pharmaceuticals plc (0001847903) (Filer)
144 - Centessa Pharmaceuticals plc (0001847903) (Subject)
SerpinPC: Ongoing registrational PRESent-2 and PRESent-3 studies for the treatment of hemophilia B; New data from ongoing Phase 2a study accepted for poster presentation at American Society of Hematology (ASH) Annual Meeting in December 2023 ORX750: Preclinical data supporting potential best-in-class profile for the treatment of narcolepsy and other sleep-wake disorders presented at World Sleep Congress; Advancing in IND-enabling studies; Clinical proof of concept data planned for 2024LockBody® Technology Platform: Ongoing Phase 1/2a study of LB101 (PD-L1xCD47) for the treatment of solid tumors BOSTON and LONDON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA
Enrollment and dosing ongoing in registrational study of SerpinPC for the treatment of hemophilia BEnrollment and dosing ongoing in Phase 1/2a Study of LB101, a PD-L1xCD47 LockBody® for the treatment of solid tumors IND-enabling activities advancing for ORX750, an oral selective orexin receptor 2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; Announces ORX750 preclinical data to be presented at World Sleep Congress in October 2023 Nominates second LockBody candidate, LB206, a conditionally bivalent PD-L1xCD3 bispecific monoclonal antibody BOSTON and LONDON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceuti
– Strong clinical momentum and cash runway into 2026 to support multiple clinical readouts across pipeline – Advancing registration program for SerpinPC to treat hemophilia B; Enrolling subjects in PRESent-5, observational feeder study Dosing subjects in ongoing Phase 1/2a clinical trial for LB101, a PD-L1xCD47 LockBody® to treat solid tumorsConducting IND enabling activities for ORX750, an orally administered, selective orexin receptor 2 (OX2R) agonist, with the potential to be a best-in-class therapy to treat narcolepsy and other sleep disorders; ORX750 profile to be presented at scientific meeting in 2023 BOSTON and LONDON, May 12, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals
– Company highlights three significant near-term milestones – – Pivotal program for SerpinPC in hemophilia B advancing; PRESent-5 observation study on track to begin this quarter – – Data readout of SerpinPC Phase 2a OLE Study with additional 18-months of continued subcutaneous treatment at American Society of Hematology (ASH) Annual Meeting in December 2022 – – IND submission for LB101, a conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody, on track for late 2022 – – Cash runway into 2026 enables multiple clinical readouts across pipeline – – Cash and cash equivalents of $444.8 million as of September 30, 2022 – BOSTON and LONDON, Nov. 10, 2022 (GLOBE
- Registrational studies of SerpinPC for treatment of Hemophilia B planned for 2H of 2022 – - Oncology pipeline advancing with novel LockBody® technology – - Announces discontinuation of ZF874 for AATD – - Multiple clinical PoC readouts expected across pipeline over next two years – – Cash and cash equivalents of $484.2 million as of June 30, 2022; Cash runway into 2026 – BOSTON and LONDON, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company with a Research & Development ("R&D") innovation engine that aims to discover, develop, and ultimately deliver impactful medicines to patients, today reported financial results
4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)
4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)
4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)
4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)
4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)
4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)
4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)
4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)
4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)
4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)
Oppenheimer analyst Francois Brisebois initiates coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with a Outperform rating and announces Price Target of $14.
Morgan Stanley analyst Matthew Harrison maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Equal-Weight and raises the price target from $8 to $11.
Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that John Crowley CPA, has been appointed Chief Financial Officer, and Gregory Weinhoff MD MBA, former Chief Financial Officer, has been appointed to the newly created role of Chief Business Officer, effective June 10, 2024.
BMO Capital analyst Kostas Biliouris maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Outperform and maintains $15 price target.
Centessa Pharmaceuticals (NASDAQ:CNTA) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.48) by 20.83 percent. This is a 15.56 percent increase over losses of $(0.45) per share from the same period last year.
Shares of Take-Two Interactive Software, Inc. (NASDAQ:TTWO) fell sharply during Friday’s session following third-quarter results. Take-Two reported third-quarter total net bookings of $1.34 billion, down 3% year-over-year. The company also revised its 2024 net bookings forecast to $5.25 billion and $5.3 billion, down from $5.45 billion and $5.55 billion earlier. Take-Two Interactive Software shares dipped 8.8% to $154.69 on Friday. Here are some other stocks moving in today's mid-day session. Gainers Sunworks, Inc. (NASDAQ:SUNW) shares jumped 267% to $0.1990. Sunworks and three subsidiaries recently made the decision to cease operations and filed for Chapter 7 bankruptcy in the Uni
Announced additional interim data from ongoing Phase 1 clinical study of ORX750, a novel orexin receptor 2 (OX2R) agonist, in acutely sleep-deprived healthy volunteers that further support best-in-class potential of ORX750 in narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH); Presentation of Phase 1 data planned for medical congress in Q2 2025Initiated Phase 2a clinical study of ORX750 in patients with NT1, NT2 and IH; Phase 2a data across all three indications expected in 2025 with first-in-class potential in NT2 and IHAdvancing ORX142 in IND-enabling studies for treatment of neurological, neurodegenerative, and psychiatric disorders; Clinical data in healthy
BOSTON and LONDON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Guggenheim Healthcare Innovation Conference Date: November 13, 2024Location: Boston, MAFireside Chat: 9:00 AM ET Event: Jefferies London Healthcare Conference Date: November 19, 2024Location: London, UKFireside Chat: 1:30 PM GMT Event: 7th Annual Evercore HealthCONx ConferenceDate: December 5, 2024Location: Miami, FLFireside Chat: 10:00 AM ET Access to the
Late-breaking poster presentation of non-human primate (NHP) data support ORX142 as novel drug candidate for the treatment of excessive daytime sleepiness (EDS) in select neurological, neurodegenerative, and psychiatric disorders BOSTON and LONDON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today shared new preclinical data from non-human primate (NHP) studies of ORX142, an investigational, novel, orexin receptor 2 (OX2R) agonist being advanced for the treatment of excessive daytime sleepiness (EDS) in select neurological, neurodeg
BOSTON and LONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the pricing of an upsized underwritten public offering of 15,254,237 of American Depositary Shares ("ADSs"), each representing one ordinary share, at a price to the public of $14.75 per ADS. The aggregate gross proceeds to Centessa from this offering are expected to be approximately $225 million, before deducting underwriting discounts and commissions and offering expenses payable by Centessa. All ADSs sold in the offering were offered by Centessa. The off
BOSTON and LONDON, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has commenced an underwritten public offering of $150 million of American Depositary Shares ("ADSs"), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of ADSs offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whethe
2.5 mg dose restored normative wakefulness with mean sleep latency of 32 minutes as measured by the Maintenance of Wakefulness Test (MWT)Favorable safety and tolerability profile with no observations of frequently reported on-target adverse events (AEs) associated with other OX2R agonists, visual disturbances or hepatotoxicity as of the data cutoff date 1PK profile supports once-daily dosing Company plans to rapidly initiate Phase 2 studies of ORX750 in patients with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) BOSTON and LONDON, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that
BOSTON and LONDON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), today announced that preclinical data from a non-human primate (NHP) study of ORX142, a highly potent and selective orexin receptor 2 (OX2R) agonist being developed to address excessive daytime sleepiness (EDS) in select neurological, neurodegenerative, and psychiatric disorders, has been accepted for a late- breaking poster presentation at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) being held September 24-27, 2024, in Seville, Spain. The poster presentation will feature, for the first time, robust preclinical data demonstrating that low doses of ORX142 promot
BOSTON and LONDON, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY. A fireside chat is scheduled for Wednesday, September 4th at 1:05 PM ET. The live audio webcast of this event, as well as an archived recording, will be available under the "Events and Publications" tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/events-presentations. Ab
Company advancing pipeline of potential best-in-class orexin receptor 2 (OX2R) agonists Initiated Phase 1 clinical study with ORX750 being developed for sleep-wake disorders; Safety and efficacy data in acutely sleep-deprived healthy volunteers assessed using Maintenance of Wakefulness Test (MWT) on track for 2H of 2024 Nominated ORX142 as development candidate; Currently in IND enabling activities for select neurological, neurodegenerative, and psychiatric disorders with excessive daytime sleepiness (EDS) SerpinPC registrational program for the treatment of hemophilia B progressing; PRESent-2 Part 1 interim analysis planned for 2024 BOSTON and LONDON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- C
BOSTON and LONDON, June 10, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that John Crowley CPA, has been appointed Chief Financial Officer, and Gregory Weinhoff MD MBA, former Chief Financial Officer, has been appointed to the newly created role of Chief Business Officer, effective June 10, 2024. "With all three of our core programs in the clinic, we believe we have solidified a strong foundation and are poised for our next exciting chapter as a company. To best position Centessa for this pivotal time, we've added key new talen